Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)vsUnited Therapeutics Corporation (UTHR)
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
$13.75
+1.70%
HEALTHCARE · Cap: $5.17B
UTHR
United Therapeutics Corporation
$549.87
+0.40%
HEALTHCARE · Cap: $23.17B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 4% more annual revenue ($3.17B vs $3.05B). UTHR leads profitability with a 40.6% profit margin vs 4.0%. UTHR trades at a lower P/E of 20.2x. UTHR earns a higher WallStSmart Score of 57/100 (C).
AMRX
Hold44
out of 100
Grade: D
UTHR
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+34.1%
Fair Value
$22.32
Current Price
$13.75
$8.57 discount
Margin of Safety
+2.5%
Fair Value
$487.82
Current Price
$549.87
$62.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 384.6% YoY
Conservative balance sheet, low leverage
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 41.7%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Areas to Watch
3.9% revenue growth
4.0% margin — thin
Premium valuation, high expectations priced in
ROE of -881.0% — below average capital efficiency
Expensive relative to growth rate
Revenue declined 1.6%
Earnings declined 12.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : AMRX
The strongest argument for AMRX centers on EPS Growth, Debt/Equity.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.
Bear Case : AMRX
The primary concerns for AMRX are Revenue Growth, Profit Margin, P/E Ratio. A P/E of 43.8x leaves little room for execution misses. Thin 4.0% margins leave little buffer for downturns.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
AMRX profiles as a value stock while UTHR is a declining play — different risk/reward profiles.
AMRX carries more volatility with a beta of 1.32 — expect wider price swings.
AMRX is growing revenue faster at 3.9% — sustainability is the question.
UTHR generates stronger free cash flow (363M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (57/100 vs 44/100), backed by strong 40.6% margins. AMRX offers better value entry with a 34.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amneal Pharmaceuticals, Inc. Class A Common Stock
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?